Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$218K Buy
10,923
+87
+0.8% +$5.8K 0.02% 305
2026
Q1
$199K Sell
10,836
-173
-2% -$12K 0.02% 287
2025
Q4
$221K Buy
11,009
+119
+1% +$7.69K 0.02% 265
2025
Q3
$216K Hold
10,890
0.02% 275
2025
Q2
$278K Buy
10,890
+2,559
+31% +$201K 0.02% 237
2025
Q1
$44.1K Sell
8,331
-1,579
-16% -$129K ﹤0.01% 550
2024
Q4
$172K Buy
9,910
+1,456
+17% +$108K 0.02% 302
2024
Q3
$56.7K Buy
8,454
+5,853
+225% +$481K 0.01% 498
2024
Q2
$295K Buy
+2,601
New +$329K 0.03% 187

Other funds holding DXCM

LRI Investments's DXCM Position: Q2 2026 in Review

LRI Investments increased its DexCom (DXCM) stake by 0.8% in Q2 2026, buying an estimated $5.8K and bringing the position to 10,923 shares worth $218K. The position accounts for 0.02% of the portfolio, ranked #305.

LRI Investments first reported a position in DXCM in Q2 2024 and has held it in 9 quarters since. The position peaked at $295K in Q2 2024. 353 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • LRI Investments held 10,923 shares of DexCom worth $218K as of Q2 2026.
  • LRI Investments bought 87 DexCom shares in Q2 2026, an estimated $5.8K.
  • DexCom made up 0.02% of LRI Investments's portfolio in Q2 2026, its #305 holding.
  • LRI Investments first reported a position in DexCom in Q2 2024 and has held it in 9 quarters since.
  • LRI Investments's DexCom position peaked at $295K in Q2 2024.
  • 353 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.